Professor El-Nasir M A Lalani, Founding Director, AKU-CRM

​Personal Pr​ofile​

Papers ​

  1. ​​​Riaz N, Idrees R, Habib S & Lalani E-N (2020)Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple-Negative Breast CancerFront. Oncol, 28 July 2020. 

  2. ​​​Barr D, Chan D, Garfinkel S, Hammatt Z, Ichikawa L, Kalichman M, Lalani E-N, Jae LI, Leung F, Mah E, Mayer T, Palittapongarnpim P, Sawicka T, Sham HM, Shastri S, Sun P, Taylor P & Tzeng O.​ First meeting in Asia of the Asia Pacific Research Integrity network. Pages 99-106 | Published Online: 14 Jan 2020.​ 

  3. Riaz N, Idrees R, Habib S, Azam I, Lalani E-NExpression of Androgen Receptor and Cancer Stem Cell Markers (CD44+/CD24- and ALDH+): Prognostic Implications in Invasive Breast CancerTranslational Oncology. 2018; 11(4): 920-929. 

  4. Ibrahim S, Siddiqui AA, Siddiqui AR, Ahmed W, Moss PAH and Lalani E-N (2016). Sociodemographic Factors Associated with IgG and IgM Seroprevalence for Human Cytomegalovirus Infection in Adult Populations of Pakistan: A Seroprevalence SurveyBMC Public Health. 2016;16:1112.  ​

  5. Sultana A, Idress R, Naqvi ZA, Azam I, Khan S, Siddiqui AA and Lalani E-N (2014). Expression of the Androgen Receptor, pAkt, and pPTEN in Breast Cancer and Their Potential in PrognosticationTranslational Oncology. 2014;7(3):355-362.

  6. Romanska H, Salagierski M, Bruton R, Abel P, Sosnowski M and Lalani E-N (2010). Doxazosin Induces Apoptosis in PTEN–positive Androgen-independent PC Cells via Inhibition of A kt ActivationCentral European Journal​​ of Urology. 2010; 63(2):91-97.

  7. Romanska H, Tiziani S, Howe RC, Günther UL, Gulzar Z and Lalani E-N (2009). Nuclear Magnetic Resonance Detects Phosphoinositide 3-Kinase/Akt-Independent Traits Common to Pluripotent Murine Embryonic Stem Cells and Their Malignant CounterpartsNeoplasia. 2009;11(12):1301–1308. ​

  8. Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD, Krcova Z, Kusinska R, Ehrmann J, Buckley CD, Kordek R, Potemski P, Eliopoulos AG, Lalani E-N and Berditchevski F. CD151 Regulates Tumorigenesis by Modulating the Communication Between Tumor Cells and EndotheliumMol Cancer Res. 2009;7(6):787-98. 

  9. El-Sheikh SS, Romanska R, Domin J, Abel P and Lalani E-NPredictive Value of PTEN and AR Co-expression of Sustained Responsiveness to Hormonal Therapy In Prostate Cancer--A Pilot Study​.  Neoplasia. 2008 Sep; 10(9):949-53.

  10. El-Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani E-N, Dearnaley D, Parmar M and Abel PD (2008). Early Hormonal Data from A Multicentre Phase II Trial Using Transdermal Patches as First-Line Hormonal Therapy in Patients with Locally Advanced Or Metastatic Prostate Cancer​. BJU Int. 2008;102(4):442-5.

  11. Rehman KU, Parmar S, Williams R, Dover S and Lalani E-N (2008). Research Training for Oral and Maxillofacial SurgeryBr J Oral Maxillofac Surg. 2008;46(4):343.

  12. Ockrim J, Lalani E-N, and Abel P (2006). Therapy Insight: Parenteral Estrogen Treatment for Prostate Cancer--A New Dawn for an Old TherapyNat Clin Pract Oncol. 2006; 3(10): 552-63. Review. 

  13. Soeiro I, Mohamedali A, Romanska HM, Lea NC, Child ES, Glassford J, Orr SJ, Roberts C, Naresh KN, Lalani E-N, Mann Dj, Watson RJ, Thomas NS and Lam EW (2006). p27Kip1 and p130 Cooperate to Regulate Hematopoietic Cell Proliferation In ​VivoMol Cell Biol. 2006; 26(16):6170-84.  

  14. Horne AW, Lalani EN, Margara RA and White JO (2006). The Effects of Sex Steroid Hormones and Interleukin-1-Beta on MUC1 Expression in Endometrial Epithelial Cell LinesReproduction. 2006 Apr;131(4):733-42. 

  15. Ockrim J, Lalani E-N, Aslam M, Stanfield N and Abel P (2006). Changes in ​​Vascular Flow After Transdermal Oestradiol Therapy for Prostate Cancer: A Mechanism for Cardiovascular Toxicity and BenefitBJU International March 2006; 97, 498-504. 

  16. Baus-Loncar M, Schmid J, Lalani E-N, Rosewell I, Goodlad RA, Stamp GW, Blin and N, Kayademir T (2005). Trefoil Factor 2 (tff2) Deficiency in Murine Digestive Tract Influences the Immune SystemCell Physiol Biochem. 2005;16(1-3):31-42. ​

  17. Lalani E-N, Poulsom R, Stamp G, Fogt F, Thomas P and Nanji AA (2005). Expression of Hepatocyte Growth Factor and its Receptor C-Met Correlates with Severity of Pathological Injury in Experimental Alcoholic Liver DiseaseInt J Mol Med. 2005 May;15(5):811-7.

  18. Ockrim JL, Lalani E-N and Abel PD (2005). Osteoporosis and Spinal Fractures in Men with Prostate Cancer: Risk Factors and Effects of Androgen Deprivation TherapyJ Urol. 2005 May;173(5):1829. 

  19. Horne AW, Lalani E-N, Margara RA, Ryder TA, Mobberley ​MA and White JO (2005). The Expression Pattern of MUC1 Glycoforms and Other Biomarkers of Endometrial Receptivity in Fertile and Infertile WomenMol Reprod Dev. 2005 Oct;72(2):216-29.

  20. Ockrim JL, Lalani E-N, Kakkar AK, Abel PD (2005). Transdermal Estradiol Therapy for Prostate Cancer Reduces Thrombophilic Activation and Protects Against ThromboembolismJ Urol. 2005 Aug;174(2):527-33; discussion 532-3. 

  21. Ockrim JL, Lalani E-N, Banks LM, Svensson WE, Blomley MJ, Patel S et al (2004). Transdermal Estradiol Improves Bone Density When Used as Single Agent Therapy for Prostate CancerJ Urol. 2004 Dec;172(6, Part 1 of 2):2203-2207.  

  22. Mubashar M, Harrington KJ, Chaudhary KS, Lalani E-N, Stamp GW, Peters AM (2004). Differential Effects of Toremifene on Doxorubicin, Vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing Breast and Head and Neck Cancer Cell LinesActa Oncol. 2004;43(5):443-52.

  23. El-Sheikh SS, Domin J, Abel P, Stamp G and Lalani E-N (2004). ErbB2: EGFR Ratio is a Critical Predictor of a Mitogenic Response to EGF in a Prostate Cancer Model – Potential Implications for the Use of Anti-ErbB2 or Dual Tyrosine Kinase InhibitorsNeoplasia. 2004 Nov-Dec; 6(6):846-53. 

  24. Baus LM, Al-azzeh E, Romanska H, Lalani E-N, Stamp G, Blin N and Kayademir T (2004). Transcriptional Control of the Intestinal Trefoil Factor (TFF3) Via Promoter Binding Sites for the Nuclear Factor kappaB and C/EBPbetaPeptides. 2004 May;25(5):849-54.  ​

  25. Siu LS, Romanska H, Abel PD, Baus-Loncar M, Kayademir T, Stamp GW, Lalani E-N (2004). TFF 2 Inhibits Apoptosis in Breast and Colorectal Cancer Cell LinesPeptides. 2004 May;25(5):855-63. ​

  26. Siu LS, Abel PD, Romanska H, Kayademir T, Blin N, Stamp GWH and Lalani E-N (2004). TFF 1 is Membrane Associated in Breast Carcinoma Cell Line MCF-7Peptides. 2004 May; 25(5): 745-53. 

  27. Khan A, Abel PD, Chaudhary K, Gulzar Z, Stamp GW and Lalani E-N (2003). Inverse Correlation between High-level Expression of Cyclin E and Proliferation Index in Transitional Cell Carcinoma of the BladderMol Pathol. 2003 Dec; 56(6):353-61.  

  28. Landles C, Chalk S, Steel JH, Rosewell I, Spencer-Dene B, Lalani E-N, Parker MG (2003). TRAP220 is Required at Distinct Embryonic Stages in Placental, Cardiac, and Hepatic DevelopmentMol Endocrinol. 2003 Dec;17(12):2418-35.

  29. El-Sheikh SS, Domin J, Abel PD, Tomtitchong P, Stamp GW and Lalani E-N (2003). Topographical Expression of Class IA and Class II Phosphoinositide 3-Kinase Enzymes in Normal Human Tissues is Consistent With a Role in DifferentiationBMC Clin Pathol. 2003 Oct 16;3(1):4.

  30. Nightingale J, Chaudhary KS, Abel PD, Stubbs AP, Romanska HM, Mitchell SE, Stamp GW and Lalani E-N (2003). Ligand Activation of the Androgen Receptor Down-regulates E-cadherin-mediated Cell Adhesion and Promotes Apoptosis of Prostatic Cancer CellsNeoplasia 2003 July-Aug; 5(4): 347-361.

  31. Ochrim JL, Lalani E-N, Laniado ME, Carter SS and Abel PD (2003). Transdermal Estradiol Therapy for Advanced Prostate Cancer– Forward to the PastJ Urol. 2003 May; 169(5):1735-7.

  32. El-Sheikh SS, Domin J, Abel P, Stamp G and Lalani E-N (2003). Androgen- Independent Prostate Cancer: Potential Role of Androgen and ErbB Signal Transduction CrosstalkNeoplasia 2003 Mar-Apr; 5(2):99-109.  

  33. Tadrous PJ, Siegel J, French PM, Shousha S, Lalani E-N and Stamp GW (2003). Fluorescence Lifetime Imaging of Unstained Tissues: Early Results in Human Breast Cancer. J Pathol. 2003 Mar;199(3):309-17.

Books/ Book Chapter​s​​

  1. Abel, PD and Lalani E-N (Eds) (2003). Prostate Cancer: Scientific and Clinical Aspects – Bridging the Gap. Imperial College Press, London, UK.  ISBN 1-86094-327-6). Contributed 5 out of 38 chapters. 

  2. Lalani E-N, Gendler SJ, Peat N, Duhig T and Taylor-Papadimitriou J (1993). Model systems for studying the potential use of the breast associated mucin PEM, in cancer therapy. In AA ed, Monoclonal application in clinical oncology (138-167). Springer Verlag.

  3. Anilkumar TV, Golding M, Sarraf C, Lalani E-N and Alison M (1994). Stem cell activation in acetylaminofluorene treated regenerating rat liver: a bile ductular reaction (163-180). In Skoutris GG (Ed), NATO ASI Series. Springer Verlag.

  4. Pignatelli M, Liu D, Nigam AK, Gagliardi G, Stamp GW and Lalani E-N (1995). Adhesion molecules in neoplasia: an overview (1-14). In Epenetos AA and Pignatelli M (Eds), Cell adhesion molecules in cancer and inflammation. Harwood Academic Publishers.

  5. Stamp GW, Lalani E-N, Hanby AM, Rasbridge S and Pignatelli M (1995). Cell adhesion molecules in mammary carcinoma (15-36). In Epenetos AA and Pignatelli M (Eds) Cell adhesion molecules in cancer and inflammation. Harwood Academic Publishers.

  6. Williams R, Elia G, Lalani E-N and Stamp GW (1995). Neoplastic and hyperplastic alterations in pancreatic ductal epithelium. In Lemoine N and Neoptolemos J (Eds) Diseases of the pancreas. Blackwell Science Ltd, Oxford.

  7. Lalani E-N and Stamp GW (1997). Role of the stroma in neoplastic growth and progression (102-124). In Lemoine N and Kirkham N (Eds) Progress in Pathology 3. Churchill Livingstone.

  8. Lalani E-N, Stubbs A and Stamp GW (1998). Molecular genetic changes in prostate cancer (113-135). In Lemoine N and Kirkham N (Eds) Progress in Pathology 4. Churchill Livingstone. 

  9. Abel PD and Lalani E-N (2003). Prostate Cancer - Some Clinical and Scientific Dilemmas (3-19) (2003). In Abel PD and Lalani E-N (Eds) Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap Part 1. Imperial College Press.

  10. Mitchell SE, Nightigale J, Abel PD and Lalani E-N (2003). Cell lines as models of prostate cancer (143-244). In Abel PD and Lalani E-N (Eds) Molecular and Cell Biology of Prostate Cancer Part 4, Ch1; Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap. Imperial College Press.

  11. Laniado ME, Lalani E-N, Abel PD (2003). Ion Channels in Prostate Cancer (339-358). In Abel PD and Lalani E-N (Eds) Molecular and Cell Biology of Prostate Cancer Part 4, Ch1; Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap. Imperial College Press.

  12. Mitchell SE, Abel PD, Lalani E-N, and Hayward SW (2003). Epithelial-Mesenchymal Interactions in Prostate Cancer (421-454). In Abel PD and Lalani E-N (Eds) Molecular and Cell Biology of Prostate Cancer Part 4, Ch 1; Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap. Imperial College Press.

  13. Chaudhary KS, Abel PD and Lalani E-N (2003). Bcl-2 family Proteins and Prostate Cancer Progression: Potential for Therapeutic Interventions (595-618). In Abel PD and Lalani E-N (Eds) Molecular and Cell Biology of Prostate Cancer Part 4, Ch1; Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap. Imperial College Press.